Page last updated: 2024-09-05

sb 203580 and MPTP Neurotoxicity Syndrome

sb 203580 has been researched along with MPTP Neurotoxicity Syndrome in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bales, KR; Bymaster, FP; Chernet, E; Dodel, RC; Du, Y; Gao, F; Lin, S; Luecke, S; Ma, Z; Nelson, DL; Paul, SM; Perry, KW; Phebus, LA; Triarhou, LC	1

Other Studies

1 other study(ies) available for sb 203580 and MPTP Neurotoxicity Syndrome

Article	Year
Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America, 2001, Dec-04, Volume: 98, Issue:25 Topics: Animals; Caspase 1; Cells, Cultured; Dopamine; Humans; Imidazoles; Male; Mice; Mice, Inbred C57BL; Minocycline; Mitogen-Activated Protein Kinases; Monoamine Oxidase; MPTP Poisoning; Nerve Degeneration; Neurons; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; Parkinsonian Disorders; Phosphorylation; Pyridines; Visual Cortex	2001

Article

Year

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease.

Proceedings of the National Academy of Sciences of the United States of America, 2001, Dec-04, Volume: 98, Issue:25

Topics: Animals; Caspase 1; Cells, Cultured; Dopamine; Humans; Imidazoles; Male; Mice; Mice, Inbred C57BL; Minocycline; Mitogen-Activated Protein Kinases; Monoamine Oxidase; MPTP Poisoning; Nerve Degeneration; Neurons; Neuroprotective Agents; Nitric Oxide; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; p38 Mitogen-Activated Protein Kinases; Parkinsonian Disorders; Phosphorylation; Pyridines; Visual Cortex

2001